14-3-3Σ Mediates G2–M Arrest Produced by 5-Aza-2′-deoxycytidine and Possesses a Tumor Suppressor Role in Endometrial Carcinoma Cells

Michael Steiner,Brett Clark,Jian-Zhong Tang,Tao Zhu,Peter E. Lobie
DOI: https://doi.org/10.1016/j.ygyno.2012.06.039
IF: 5.304
2012-01-01
Gynecologic Oncology
Abstract:Objectives. To determine the effect of 5-aza-2'-deoxycytidine (DAC) on human endometrial carcinoma cell (HECC) oncogenicity and demonstrate a molecular mechanism by which DAC modulates HECC oncogenicity.Methods. The effect of DAC was tested on HECC RL95-2, AN3, Ishikawa and ECC1 cells. The role of 14-3-3 sigma on HECC oncogenicity in response to DAC treatment was evaluated in RL95-2 and AN3 cells after forced expression or silencing of 14-3-3 sigma gene expression.Results. Treatment of HECC with DAC produced non-cytotoxic cell growth inhibition and G2/M cell cycle arrest. This effect was strongly correlated with increased expression of p21 and 14-3-3 sigma. Silencing of 14-3-3 sigma induced cellular proliferation and reduced the effect of DAC on cell cycle arrest in G2/M phases. Conversely, forced expression of 14-3-3 sigma showed the opposite effect. Furthermore, forced expression of 14-3-3 sigma in human endometrial cell lines reduced cell growth and colony formation.Conclusions. We suggest that 14-3-3 sigma in HECC suppresses cell proliferation and mediates DAC induced G2/M arrest and inhibition of cell proliferation in HECC. (C) 2012 Elsevier Inc. All rights reserved.
What problem does this paper attempt to address?